Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study

Patients with chronic liver disease (CLD) are at a greater risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. This study investigated the antibody response to inactivated SARS-CoV-2 vaccination in a long-term prospective cohort of CLD patients. The seropositivity ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yinuo, Li, Xuemei, Zhao, Xinya, Liu, Yiqing, Zhao, Tong, Zhu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234691/
https://www.ncbi.nlm.nih.gov/pubmed/37269896
http://dx.doi.org/10.1016/j.clinre.2023.102150
Descripción
Sumario:Patients with chronic liver disease (CLD) are at a greater risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. This study investigated the antibody response to inactivated SARS-CoV-2 vaccination in a long-term prospective cohort of CLD patients. The seropositivity rates and antibody concentrations of anti-SARS-CoV-2 NAbs were similar among patients with different severity of CLD 6 months after the third vaccination. In addition, older CLD patients appeared to have lower antibody responses. These data might be helpful to inform vaccine decisions for patients with chronic liver disease.

Ejemplares similares